Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the predominant cause of familial Parkinson's disease. We previously reported that parkin-/- mice exhibit nigrostriatal deficits in the absence of nigral degeneration. Parkin has been shown to function as an E3 ubiquitin ligase. Loss of parkin function, therefore, has been hypothesized to cause nigral degeneration via an aberrant accumulation of its substrates. Here we employed a proteomic approach to determine whether loss of parkin function results in alterations in abundance and/or modification of proteins in the ventral midbrain of parkin-/- mice. Two-dimensional gel electrophoresis followed by mass spectrometry revealed decreased abundance of a number of proteins involved in mitochondrial function or oxidative stress. Consistent with reductions in several subunits of complexes I and IV, functional assays showed reductions in respiratory capacity of striatal mitochondria isolated from parkin-/- mice. Electron microscopic analysis revealed no gross morphological abnormalities in striatal mitochondria of parkin-/- mice. In addition, parkin-/- mice showed a delayed rate of weight gain, suggesting broader metabolic abnormalities. Accompanying these deficits in mitochondrial function, parkin-/- mice also exhibited decreased levels of proteins involved in protection from oxidative stress. Consistent with these findings, parkin-/- mice showed decreased serum antioxidant capacity and increased protein and lipid peroxidation. The combination of proteomic, genetic, and physiological analyses reveal an essential role for parkin in the regulation of mitochondrial function and provide the first direct evidence of mitochondrial dysfunction and oxidative damage in the absence of nigral degeneration in a genetic mouse model of Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, mitophagy deficiency favored by ablation of Prkn (Palacino et al, 2004; Pickrell et al, 2015) or Pink1 (Gautier et al, 2008) sensitizes mice to oxidative stress, while worsening neural damage when combined with mitochondrial dysfunction (mitochondrial DNA [mtDNA] mutator‐prkn/parkin‐KO mice) (Pickrell et al, 2015).”
From Autophagy in major human diseases (2021) · cites this paper as Palacino et al, 2004
In the citing paper
“Both Pink1 and Parkin knockout mice exhibit increased ROS levels and mitochondrial dysfunction (43, 44), and persistent increased ROS is one of the important factors in accelerating cellular senescence (42, 45).”
From Impaired mitophagy leads to cigarette smoke stress‐induced cellular senescence: implications for chronic obstructive pulmonary disease (2015) · cites this paper as [43]
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., & Pallanck, L. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737556100 · Cited by 1,203
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Research works printed but not linked: 5
- Jenner, 1996, Neurology, 47, 5161
- Koller, 1986, Neurology, 36
- Darios, 2003, Hum. Mol. Genet., 12, 517, 10.1093/hmg/ddg044 · doi:10.1093/hmg/ddg044 · Paper page
- Klose, 1999, Methods Mol. Biol., 112, 67
- Dubin, 1989, Mol. Cell. Biol., 9, 1083
Cited by
Items 101–200 of 1,000
Molecular pathogenesis of Parkinson disease: insights from genetic studies
Gasser, T. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001148 · Cited by 290
Oxidative Stress in Neurodegeneration
Shukla, V., Mishra, S. K., & Pant, H. C. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2011/572634 · Cited by 288
Parkin Interacts with Ambra1 to Induce Mitophagy
Van Humbeeck, C., Cornelissen, T., Hofkens, H., Mandemakers, W., Gevaert, K., De Strooper, B., & Vandenberghe, W. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1917-11.2011 · Cited by 287
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Aviles-Olmos, I., Limousin, P., Lees, A., & Foltynie, T. (2013) · Brain · doi:10.1093/brain/aws009 · Cited by 283
Parkin and mitophagy in cancer
Bernardini, J. P., Lazarou, M., & Dewson, G. (2017) · Oncogene · doi:10.1038/onc.2016.302 · Cited by 281
Reactive Oxygen Species: Stuck in the Middle of Neurodegeneration
Patten, D. A., Germain, M., Kelly, M. A., & Slack, R. S. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100498 · Cited by 278
Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease
Dodson, M. W., & Guo, M. (2007) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2007.04.010 · Cited by 278
Lau, Y.-S., Patki, G., Das-Panja, K., Le, W.-D., & Ahmad, S. O. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07626.x · Cited by 275
“mice, ROS levels are elevated; oxidative damage to the mitochondria and DA neuron apoptosis are exhibited (Palacino et al., 2004).”
BackgroundMitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects
Borsche, M., Pereira, S. L., Klein, C., & Grünewald, A. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-201981 · Cited by 275
The genetic background of Parkinson's disease: current progress and future prospects
Kalinderi, K., Bostantjopoulou, S., & Fidani, L. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12563 · Cited by 273
Parkin enhances mitochondrial biogenesis in proliferating cells
Kuroda, Y., Mitsui, T., Kunishige, M., Shono, M., Akaike, M., Azuma, H., & Matsumoto, T. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl006 · Cited by 268
Ahmad, T., Sundar, I. K., Lerner, C. A., Gerloff, J., Tormos, A. M., Yao, H., & Rahman, I. (2015) · The FASEB Journal · doi:10.1096/fj.14-268276 · Cited by 264
“Both Pink1 and Parkin knockout mice exhibit increased ROS levels and mitochondrial dysfunction (43, 44), and persistent increasedROS is one of the important factors in accelerating cellular senescence (42, 45).”
BackgroundThe ubiquitin–proteasome pathway in Parkinson's disease and other neurodegenerative diseases
Ross, C. A., & Pickart, C. M. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.10.006 · Cited by 261
Absence of nigral degeneration in aged parkin/DJ‐1/PINK1 triple knockout mice
Kitada, T., Tong, Y., Gautier, C. A., & Shen, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06350.x · Cited by 261
Self-citationDysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Alecu, I., & Bennett, S. A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00328 · Cited by 258
Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration
Stevens, D. A., Lee, Y., Kang, H. C., Lee, B. D., Lee, Y.-I., Bower, A., Jiang, H., Kang, S.-U., Andrabi, S. A., Dawson, V. L., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500624112 · Cited by 257
Ubiquitination in postsynaptic function and plasticity
Mabb, A. M., & Ehlers, M. D. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100109-104129 · Cited by 255
Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., Hoener, M., Rodrigues, C. M. P., Alfonso, A., Steer, C., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505910200 · Cited by 255
Genetic clues to the pathogenesis of Parkinson's disease
Vila, M., & Przedborski, S. (2004) · Nature Medicine · doi:10.1038/nm1068 · Cited by 255
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis
Banerjee, R., Starkov, A. A., Beal, M. F., & Thomas, B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.007 · Cited by 253
Molecular pathogenesis of Parkinson's disease
Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi308 · Cited by 251
Transcriptional responses to oxidative stress: Pathological and toxicological implications
Ma, Q. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.004 · Cited by 251
Etiology of Parkinson’s disease
Schapira, A. H. V. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s10 · Cited by 250
Lewy body Parkinson's disease in a large pedigree with 77Parkin mutation carriers
Pramstaller, P. P., Schlossmacher, M. G., Jacques, T. S., Scaravilli, F., Eskelson, C., Pepivani, I., Hedrich, K., Adel, S., Gonzales-McNeal, M., Hilker, R., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20587 · Cited by 247
Ko, H. S., von Coelln, R., Sriram, S. R., Kim, S. W., Chung, K. K. K., Pletnikova, O., Troncoso, J., Johnson, B., Saffary, R., Goh, E. L., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2172-05.2005 · Cited by 247
Mitochondrial dysfunction in neurodegenerative diseases and cancer
de Moura, M. B., dos Santos, L. S., & Van Houten, B. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20575 · Cited by 243
Calcium homeostasis, selective vulnerability and Parkinson's disease
Chan, C. S., Gertler, T. S., & Surmeier, D. J. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.01.006 · Cited by 237
Poulogiannis, G., McIntyre, R. E., Dimitriadi, M., Apps, J. R., Wilson, C. H., Ichimura, K., Luo, F., Cantley, L. C., Wyllie, A. H., Adams, D. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009941107 · Cited by 236
Mutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts
Rakovic, A., Grünewald, A., Kottwitz, J., Brüggemann, N., Pramstaller, P. P., Lohmann, K., & Klein, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016746 · Cited by 235
Radical medicine: treating ageing to cure disease
Finkel, T. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1763 · Cited by 234
“Similarly, in both Drosophila melanogaster and mouse models of parkin deficiency, there is specific evidence for mitochondrial defect”
BackgroundParkin-induced mitophagy in the pathogenesis of Parkinson disease
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2009) · Autophagy · doi:10.4161/auto.5.5.8505 · Cited by 231
Animal models of Parkinson’s disease progression
Meredith, G. E., Sonsalla, P. K., & Chesselet, M.-F. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0350-x · Cited by 228
Evolving and Expanding the Roles of Mitophagy as a Homeostatic and Pathogenic Process
Gustafsson, Å. B., & Dorn, G. W. (2019) · Physiological Reviews · doi:10.1152/physrev.00005.2018 · Cited by 228
Calì, T., Ottolini, D., Negro, A., & Brini, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.004 · Cited by 227
Evaluation of Models of Parkinson's Disease
Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., & Khurana, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00503 · Cited by 226
Van Laar, V. S., Arnold, B., Cassady, S. J., Chu, C. T., Burton, E. A., & Berman, S. B. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq531 · Cited by 225
Pathogenic mutations in Parkinson disease
Tan, E.-K., & Skipper, L. M. (2007) · Human Mutation · doi:10.1002/humu.20507 · Cited by 223
Inflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease
Surmeier, D. J., Guzman, J. N., & Sanchez-Padilla, J. (2010) · Cell Calcium · doi:10.1016/j.ceca.2009.12.003 · Cited by 222
Hattingen, E., Magerkurth, J., Pilatus, U., Mozer, A., Seifried, C., Steinmetz, H., Zanella, F., & Hilker, R. (2009) · Brain · doi:10.1093/brain/awp293 · Cited by 222
Berg, D., Youdim, M. B. H., & Riederer, P. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0976-5 · Cited by 220
Parkin as a tumor suppressor gene for hepatocellular carcinoma
Fujiwara, M., Marusawa, H., Wang, H.-Q., Iwai, A., Ikeuchi, K., Imai, Y., Kataoka, A., Nukina, N., Takahashi, R., & Chiba, T. (2008) · Oncogene · doi:10.1038/onc.2008.199 · Cited by 218
Ahmed, S., Kwatra, M., Ranjan Panda, S., Murty, U. S. N., & Naidu, V. G. M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.09.017 · Cited by 217
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Advancement in the modelling and therapeutics of Parkinson’s disease
Rai, S. N., & Singh, P. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101752 · Cited by 213
Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction
Park, J., Kim, S. Y., Cha, G.-H., Lee, S. B., Kim, S., & Chung, J. (2005) · Gene · doi:10.1016/j.gene.2005.06.040 · Cited by 213
The role of free radicals in the aging brain and Parkinson’s Disease: Convergence and parallelism
Kumar, H., Lim, H.-W., More, S. V., Kim, B.-W., Koppula, S., Kim, I. S., & Choi, D.-K. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130810478 · Cited by 212
“However, when the entire brain was analyzed, increased protein oxidation occurred in parkin KO mice at 18–20 months [61] and lipid peroxidation occurred in aged parkin KO mice [61].”
BackgroundParkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells
Kim, K.-Y., Stevens, M. V., Akter, M. H., Rusk, S. E., Huang, R. J., Cohen, A., Noguchi, A., Springer, D., Bocharov, A. V., Eggerman, T. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44736 · Cited by 211
Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder
Klein, C., & Schlossmacher, M. G. (2007) · Neurology · doi:10.1212/01.wnl.0000271880.27321.a7 · Cited by 211
Oxidative stress factors in Parkinson’s disease
Dorszewska, J., Kowalska, M., Prendecki, M., Piekut, T., Kozłowska, J., & Kozubski, W. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.300980 · Cited by 210
The disulfide relay system of mitochondria is connected to the respiratory chain
Bihlmaier, K., Mesecke, N., Terziyska, N., Bien, M., Hell, K., & Herrmann, J. M. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200707123 · Cited by 207
“Among the disorders related to mitochondria are Parkinson’s disease (Palacino et al., 2004), Alzheimer’s disease (Anandatheerthavarada et al.”
BackgroundMitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases
Martin, L. J. (2010) · Pharmaceuticals · doi:10.3390/ph3040839 · Cited by 206
Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6
Hoepken, H.-H., Gispert, S., Morales, B., Wingerter, O., Del Turco, D., Mülsch, A., Nussbaum, R. L., Müller, K., Dröse, S., Brandt, U., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.007 · Cited by 203
Oxidative and nitrative protein modifications in Parkinson's disease
Danielson, S. R., & Andersen, J. K. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.005 · Cited by 202
Mitochondria in Neurodegeneration
Lezi, E., & Swerdlow, R. H. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-2869-1_12 · Cited by 198
Antioxidants protect PINK1 -dependent dopaminergic neurons in Drosophila
Wang, D., Qian, L., Xiong, H., Liu, J., Neckameyer, W. S., Oldham, S., Xia, K., Wang, J., Bodmer, R., & Zhang, Z. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604661103 · Cited by 197
Animal Models of Parkinson’s Disease
Konnova, E. A., & Swanberg, M. (2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch5 · Cited by 198
Greene, J. C., Whitworth, A. J., Andrews, L. A., Parker, T. J., & Pallanck, L. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi074 · Cited by 194
Franco-Iborra, S., Vila, M., & Perier, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00342 · Cited by 194
Genetics of Parkinsonʼs disease
Gasser, T. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000170951.08924.3d · Cited by 192
Modelling of Parkinson's disease in mice
Chesselet, M.-F., & Richter, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70227-7 · Cited by 192
Animal models of Parkinson's disease
Jackson-Lewis, V., Blesa, J., & Przedborski, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70057-8 · Cited by 191
Apoptotic mechanisms in mutant LRRK2-mediated cell death
Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carrì, M. T., & Barone, P. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm080 · Cited by 190
The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax
Johnson, B. N., Berger, A. K., Cortese, G. P., & LaVoie, M. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113248109 · Cited by 189
Whitworth, A. J., Lee, J. R., Ho, V. M.-W., Flick, R., Chowdhury, R., & McQuibban, G. A. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000109 · Cited by 189
Chen, L., Xie, Z., Turkson, S., & Zhuang, X. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0089-14.2015 · Cited by 187
Mitochondrial DNA damage and repair in neurodegenerative disorders
Yang, J.-L., Weissman, L., Bohr, V. A., & Mattson, M. P. (2008) · DNA Repair · doi:10.1016/j.dnarep.2008.03.012 · Cited by 186
Mitochondrial translocation of α-synuclein is promoted by intracellular acidification
Cole, N. B., DiEuliis, D., Leo, P., Mitchell, D. C., & Nussbaum, R. L. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.03.012 · Cited by 185
“These include PINK1 [8], DJ-1 [9,10], parkin [11,12], and Omi/HtrA2 [13].”
BackgroundRegulation of PINK1-Parkin-mediated mitophagy
Springer, W., & Kahle, P. J. (2011) · Autophagy · doi:10.4161/auto.7.3.14348 · Cited by 184
Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio)
Flinn, L., Mortiboys, H., Volkmann, K., Koster, R. W., Ingham, P. W., & Bandmann, O. (2009) · Brain · doi:10.1093/brain/awp108 · Cited by 184
Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect
Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., & Chesselet, M.-F. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.008 · Cited by 183
The role of mitochondria in inherited neurodegenerative diseases
Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03990.x · Cited by 180
Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage
Stichel, C. C., Zhu, X.-R., Bader, V., Linnartz, B., Schmidt, S., & Lubbert, H. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm083 · Cited by 179
Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
Van Bulck, M., Sierra-Magro, A., Alarcon-Gil, J., Perez-Castillo, A., & Morales-Garcia, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030719 · Cited by 178
Lu, X.-H., Fleming, S. M., Meurers, B., Ackerson, L. C., Mortazavi, F., Lo, V., Hernandez, D., Sulzer, D., Jackson, G. R., Maidment, N. T., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5351-08.2009 · Cited by 178
The role of the p53 tumor suppressor in metabolism and diabetes
Kung, C.-P., & Murphy, M. E. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0324 · Cited by 178
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair
Rothfuss, O., Fischer, H., Hasegawa, T., Maisel, M., Leitner, P., Miesel, F., Sharma, M., Bornemann, A., Berg, D., Gasser, T., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp327 · Cited by 177
Sandebring, A., Thomas, K. J., Beilina, A., van der Brug, M., Cleland, M. M., Ahmad, R., Miller, D. W., Zambrano, I., Cowburn, R. F., Behbahani, H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005701 · Cited by 176
Mandemakers, W., Morais, V. A., & De Strooper, B. (2007) · Journal of Cell Science · doi:10.1242/jcs.03443 · Cited by 176
Antioxidant gene therapy against neuronal cell death
Navarro-Yepes, J., Zavala-Flores, L., Anandhan, A., Wang, F., Skotak, M., Chandra, N., Li, M., Pappa, A., Martinez-Fong, D., Del Razo, L. M., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.007 · Cited by 176
Mitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175
Williams, J. A., Ni, H.-M., Ding, Y., & Ding, W.-X. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00108.2015 · Cited by 175
DNA repair, mitochondria, and neurodegeneration
Weissman, L., de Souza-Pinto, N. C., Stevnsner, T., & Bohr, V. A. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.061 · Cited by 172
Hu, Y., Li, X.-C., Wang, Z.-H., Luo, Y., Zhang, X., Liu, X.-P., Feng, Q., Wang, Q., Yue, Z., Chen, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7861 · Cited by 172
Freeman, L. R., & Keller, J. N. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.12.009 · Cited by 172
Mitochondrial quality control: from molecule to organelle
Roca-Portoles, A., & Tait, S. W. G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03775-0 · Cited by 172
Genetic mouse models of parkinsonism: Strengths and limitations
Fleming, S. M., Fernagut, P.-O., & Chesselet, M.-F. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.495 · Cited by 172
Cookson, M. R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009415 · Cited by 170
“Unbiased assays of the proteome also highlighted mitochondrial dysfunction in parkin knockout mice, although without such dramatic morphological effects as seen in flies (Palacino et al. 2004).”
BackgroundRedox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications
Butterfield, D. A., Perluigi, M., Reed, T., Muharib, T., Hughes, C. P., Robinson, R. A. S., & Sultana, R. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4109 · Cited by 168
Update on the genetics of Parkinson's disease
Gasser, T. (2007) · Movement Disorders · doi:10.1002/mds.21676 · Cited by 168
The genetics of Parkinson disease: implications for neurological care
Klein, C., & Schlossmacher, M. G. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0126 · Cited by 168
Stauber, J., Lemaire, R., Franck, J., Bonnel, D., Croix, D., Day, R., Wisztorski, M., Fournier, I., & Salzet, M. (2008) · Journal of Proteome Research · doi:10.1021/pr070464x · Cited by 168
Parkin and PINK1 functions in oxidative stress and neurodegeneration
Barodia, S. K., Creed, R. B., & Goldberg, M. S. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.12.004 · Cited by 167
Self-citationFai Poon, H., Frasier, M., Shreve, N., Calabrese, V., Wolozin, B., & Butterfield, D. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.009 · Cited by 165
Perfeito, R., Cunha-Oliveira, T., & Rego, A. C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.042 · Cited by 164
Biology of Mitochondria in Neurodegenerative Diseases
Martin, L. J. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00005-9 · Cited by 163
Meng, F., Yao, D., Shi, Y., Kabakoff, J., Wu, W., Reicher, J., Ma, Y., Moosmann, B., Masliah, E., Lipton, S. A., et al. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-34 · Cited by 163
Johnson-Lyles, D. N., Peifley, K., Lockett, S., Neun, B. W., Hansen, M., Clogston, J., Stern, S. T., & McNeil, S. E. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.08.008 · Cited by 163
Jiang, Z., Hu, Z., Zeng, L., Lu, W., Zhang, H., Li, T., & Xiao, H. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.011 · Cited by 163
Metadata
- Authors
- Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Shen, Jie
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 279
- Issue
- 18
- Pages
- 18614-18622
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2140647923
- Cited by
- 995
- References
- 66
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 34 · 2023: 29 · 2022: 27 · 2021: 44 · 2020: 51 · 2019: 39 · 2018: 41 · 2017: 32 · 2016: 41 · 2015: 41 · 2014: 42 · 2013: 60 · 2012: 49
- FWCI
- 42.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6031 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- Parkin, Parkinson's disease, mitochondrial dysfunction, oxidative stress, E3 ubiquitin ligase, nigrostriatal pathway, complex I, cytochrome c oxidase, respiratory capacity, lipid peroxidation, protein peroxidation, serum antioxidant capacity, metabolic abnormalities
- MeSH terms
- Animals, Antioxidants, Basal Ganglia, Mitochondria, Oxidative Phosphorylation, Parkinson Disease, Protein Processing, Post-Translational, Weight Gain, Reactive Oxygen Species, Mice, Knockout, Oxidative Stress, Cell Respiration, Mitochondrial Proteins, Mitochondrial Diseases, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.